TRex Bio prices $117M IPO to support immune drug work
TRex Bio priced a $117 million initial public offering to support its work on regulatory T cell-based treatments for immune-mediated diseases.
TRex Bio
Private
Clinical-stage immunoregulatory therapeutics company built on tissue regulatory T cell biology, combining high-resolution human tissue sequencing, computational biology and translational assay systems in its Deep Biology platform.
Company Info
Sector:Biotechnology / Immunology
Headquarters:South San Francisco, California, USA
Founded:2018
Website:trex.bio/
Clinical Development Pipeline
TRB-061
Target: TNFR2 agonistTRB-031 / TRB-041 / TRB-051
Target: Tissue Treg modulation (partnered with Eli Lilly)Recent News
TRrexBio's IPO Bags $116M to Bring the Immune System Back Into Balance
TRrexBio's IPO Bags $116M to Bring the Immune System Back Into Balance
Leadership Team
Johnston Erwin
Chief Executive Officer
Laura Berner
Chief Operating Officer